CompaniesOtherUpdated Oct 7, 2026

KymaThera

Private. KymaThera is a biotechnology company focused on discovering and developing precision medicines against well-characterized targets that drive human disease.

Last round: $80M Series B
Backed by: Alta Partners
Launched: Not recorded
People: 6

Overview

Updated Oct 7, 2026

Every fact carries a numbered source. Where we can't source something, it says so.

Identity fields from the company record are sourced where a source is recorded; those have no number.

Website: kymathera.com opens in a new tab²
Headquarters: San Diego · as of 2026-10-06³
Stage: Series B · as of 2026-10-06³
Total raised: more than $100 million · as of 2026-10-06³
Sector: Not recorded
Geography: San Diego
Founded: Not recorded

Funding

How much has KymaThera raised?

Rounds and backers, each sourced.

Rounds

2026-10-06
Series B · $80M raised³
Led by Alta Partners
2024
Series A · Raised Not recorded³
Led by Foresite Capital · Venrock

Who backs KymaThera?

Alta PartnersLed the Series B, 2026-10-06³
Foresite CapitalLed the Series A, 2024³
VenrockLed the Series A, 2024³

Opportunities For accredited investors

Ways to invest in this company through an Alphaneo vehicle, when one exists. This section looks the same on every company page until you have an accredited profile.

For accredited investors

Opportunities, terms and data rooms are shown to accredited investors. Creating a profile takes two minutes, and you’re notified first when anything opens.

No live opportunities right now. Accredited investors are notified first when one opens.

Create an accredited profile

A vehicle is never smaller than $1,000,000.

People

Who founded and leads KymaThera?

Names and titles only, each sourced.

Shawn Ouyang, Ph.D.Founder, Senior Director Discovery Chemistry¹
Cassandra Choe-Juliak, M.D., M.S.Chief Medical Officer¹
Michael GeremiaChief Financial Officer¹
Brooke Grandinetti, Ph.D.Founder, Vice President Biology¹
Jason M. Cox, Ph.D.Founder, Chief Scientific Officer¹
Rob Kania, Ph.D.Founder, Chief Executive Officer¹

Sources

Every claim on this page traces to one of these. The numbers match the citations above.

1
Team at KymaThera opens in a new tabPeople · accessed Oct 7, 2026
2
KymaThera | Advancing the Next Wave of Precision Therapeutics opens in a new tabWebsite · accessed Oct 7, 2026
3
KymaThera Announces $80 Million Series B Financing to Advance K-1728, a Next-Generation Pan-Mutant Selective PI3Kα Inhibitor, for Cancer and Vascular Malformations opens in a new tabHeadquarters, Stage, Total raised, Funding · accessed Oct 7, 2026